People: Merck KGaA (MKGAY.PK)

Summary

Name	Age	Since	Current Position
Rolf Krebs	73	2009	Chairman of the Supervisory Board
Karl-Ludwig Kley	62	2007	Chairman of the Executive Board, General Partner
Heiner Wilhelm		2008	Vice Chairman of the Supervisory Board, Employee Representative
Matthias Zachert	45	2011	Member of the Executive Board, Chief Financial Officer
Kai Beckmann	47	2011	Member of the Executive Board, Chief Administration Officer, Head of Group Human Resources
Constantin Fest			Head of Investor Relations
Stefan Oschmann	55	2011	Member of the Executive Board, General Partner, Head of Pharmaceuticals
Bernd Reckmann	58	2007	Member of the Executive Board, Head of the Chemicals Business Sector, General Partner
Crocifissa Attardo		2009	Member of the Supervisory Board, Employee Representative
Mechthild Auge		2009	Member of the Supervisory Board, Employee Representative
Johannes Baillou			Member of the Supervisory Board
Frank Binder			Member of the Supervisory Board
Wolfgang Buechele	54	2009	Member of the Supervisory Board
Michael Fletterich		1998	Member of the Supervisory Board, Employee Representative
Michaela Freifrau von Glenck			Member of the Supervisory Board
Edeltraud Glaenzer			Member of the Supervisory Board, Employee Representative
Juergen Glaser		2012	Member of the Supervisory Board
Hans-Juergen Leuchs		2009	Member of the Supervisory Board
Albrecht Merck		2005	Member of the Supervisory Board
Karl-Heinz Scheider		2009	Member of the Supervisory Board, Employee Representative
Theo Siegert	66	2006	Member of the Supervisory Board
Berthold Wagner		2012	Member of the Supervisory Board

» Insider Trading

Biographies

Name	Description
Rolf Krebs	Prof. Dr. Rolf Krebs has been Chairman of the Supervisory Board at Merck KGaA since July 1, 2009. He has been Member of the Supervisory Board at Merck KGaA since July 1, 2006. He is retired Physician. He graduated from Johannes Gutenberg-Universitat Mainz with a Doctorate of Science degree in Medicine. He is Chairman of the Supervisory Board of Epigenomics AG and Ganymed Pharmaceuticals AG. He is Member of the Supervisory Board of Merz GmbH & Co. KGaA, Senator GmbH &Co KGaA and Merz Pharmaceuticals GmbH. He is on the Board of Partners at E. Merck KG and on the Board of Air Liquide S.A. He is Chairman of the Research and Development Committee, as well as Member of the Personnel Committee at the Company.
Karl-Ludwig Kley	Dr. Karl-Ludwig Kley has been Chairman of the Executive Board and General Partner of Merck KGaA since April 27, 2007. He studied Law at Ludwig-Maximiliams-Universitaet Muenchen, from where he graduated with Bachelor degree, in 1979, and with Doctorate in Philosophy degree in 1986. He is Lawyer by profession. He has served as Member of the Supervisory Board of the Company from March 27, 2004 till June 30, 2006. He has served as Vice Chairman of the Executive Board of the Company from September 1, 2006 till April 27, 2007. He is responsible for Information Services, global Human Resources, Legal and Compliance, Patents, Auditing and Risk Management, Strategic Planning, In-house Consulting, Corporate Communications, Environment, Health and Safety. He is Member of the Supervisory Board of Bertelsmann AG and has been Vice Chairman of the Supervisory Board of BMW AG since May 18, 2010. He is Chairman of the Supervisory Board of 1. FC Koeln GmbH & Co KGaA. Prior to completing his studies, he completed an industrial business apprenticeship at Siemens AG. After completing his practical training as Lawyer in Hamburg and Johannesburg, from 1982 he worked in Corporate Finance and as Assistant to the Chairman of the Management Board at Bayer AG. After working abroad as Chief Financial Officer at Bayer in Japan, from 1987 to 1991, he held a number of senior management positions in the Pharmaceutical division in Sales and Marketing and, from 1994 to 1997, as Managing Director of the Italian subsidiary. Subsequently, he was in charge of Corporate Finance and Investor Relations at Bayer headquarters. In 1998, he joined the Executive Board of Lufthansa AG as Chief Financial Officer. He is also Member of the Presidential Council of the German Chemical Industry Association (VCI). He is also Member of the Executive Board and General Partner of E. Merck KG.
Heiner Wilhelm	Mr. Heiner Wilhelm has been Vice Chairman of the Supervisory Board and Employee Representative of Merck KGaA since 2008. He became Member of the Supervisory Board in December 2007. Mr. Heiner Wilhelm was appointed as Chairman of the Works Council and the Group Works Council on July 1, 2007.
Matthias Zachert	Mr. Matthias Zachert has been Chief Financial Officer and Member of the Executive Board of Merck KGaA since June 1, 2011. He is responsible for Group Controlling and Risk Management; Corporate Finance, Merges & Acquisition and Treasury; Group Taxes; Group Insurance; Group Procurement; Investor Relations Following an industrial management apprenticeship at Mercedes-Benz AG, he studied business administration with a concentration in finance and international management from 1990 to 1995. He holds a degree in business administration (Diplom-Kaufmann). Following his studies, Mr. Zachert joined the former Hoechst AG. He held various senior management positions in the pharmaceutical business, including responsibility for the IPO project to spin of the subgroup Hoechst Marion Roussel (HMR). In the course of the combination of HMR and Rhone-Poulenc Rorer to form Aventis Pharma AG, Mr. Zachert became Chief Financial Officer of the International Region based in Paris, France. In 2002, Mr. Zachert transferred to Kamps AG as Chief Financial Officer. In this position, he contributed to the strategic repositioning of the company. Mr. Zachert was appointed Chief Financial Officer of Lanxess AG in 2004. At Lanxess, he was responsible for setting up the global finance organization as well as for the newly established company’s capital market communications. In addition, he played a key role in restructuring the portfolio and internationalizing Lanxess in recent years. He is Member of the Scientific Committee Institut fuer Unternehmungsplanung (IUP) and Member of German Financial Executives Institute (Gesellschaft für Finanzwirtschaft in der Unternehmensfuehrung e.V., GEFIU).
Kai Beckmann	Dr. Kai Beckmann has been Chief Administration Officer, Member of the Executive Board and Head of Group Human Resources at Merck KGaA since April 1, 2011. He is responsible for Group Human Resources; Group Information Services; Site Management Darmstadt and Gernsheim; Inhouse Consulting in the region EMEA (Europe, Middle East, Africa). He studied computer science at the Technische Universitaet Darmstadt from 1984 to 1989. He began his career at the Company in 1989 as an Information Technology system consultant. In 1998, he earned a doctorate in economics while working. As of 1999 Dr. Beckmann headed the main department Information Management and Consulting. In 2004 Dr. Beckmann became Managing Director of the Merck subsidiaries in Singapore and Malaysia. As of 2007, he became the first Chief Information Officer of the Merck Group with responsibility for Corporate Information Services. He is Member of the Board of Federal Employers' Association for the German Chemical Industry (Bundesarbeitgeberverband Chemie e.V., BAVC) and Employers' Association for the Chemical and Related Industries in the State of Hesse (Arbeitgeberverband Chemie und verwandte Industrien fuer das Land Hessen e.V., HessenChemie).
Constantin Fest
Stefan Oschmann	Dr. Stefan Oschmann has been Member of the Executive Board, General Partner and Head of the Pharmaceuticals business sector at Merck KGaA since January 1, 2011. He is responsible for Europe, the United States (Pharmaceuticals), Canada, Latin and Central America, as well as Africa and Middle East. After earning a degree in Veterinary Medicine and a Doctorate from Ludwig-Maximilians-Universitaet Muenchen, he took on a position at the International Atomic Energy Agency IAEA. In 1989 he joined the American company Merck & Co. (outside North America: MSD – Merck Sharp & Dohme). Following various positions in Belgium, the Netherlands and Austria he was appointed Vice President of Central and Eastern Europe in 1998 and Vice President of Europe in 1999. Until 2005 he was also in charge of the German business of Merck & Co. In 2005 he moved to the headquarters of Merck & Co., taking on the role of Senior Vice President in charge of Worldwide Human Health Marketing. In 2006 he became Member of Senior Management and Corporate Officer, in charge of Merck & Co.’s business in Europe, the Middle East, Africa and Canada. As of 2009, Dr. Oschmann served as President of Emerging Markets for Merck & Co. Since January 10, 2011 he is Chairman of the Board at Merck Serono S.A.
Bernd Reckmann	Dr. Bernd Reckmann has been Member of the Executive Board, General Partner and Head of the Chemicals Business Sector at Merck KGaA since January 1, 2007. He studied Biochemistry at Gottfried Wilhelm Leibniz Universitaet Hannover, Germany, from 1976 to 1984, and completed his studies with a doctorate. He has worked in the Biochemistry Department at the University of Bayreuth from 1984 to 1986. Dr. Reckmann joined the diagnostics research unit of Merck in Darmstadt in 1986. From 1993 to 1998, he worked in Marketing and Sales within the laboratory and diagnostics business. He was appointed Head of the Life Science Products division in 1998. He became Head of Strategic Innovation at Merck in 2004 before being appointed president of the Merck companies in Korea. He is responsible for German region, including Human Resources, Site Management Darmstadt and Gernsheim, Asia, Chemicals division in the United States, Russia, Australia and New Zealand. He has been on the Board of Millipore Corp. in the United States and Millipore Corp. in Puerto Rico since July 2010.
Crocifissa Attardo	Ms. Crocifissa Attardo has been Member of the Supervisory Board and Employee Representative of Merck KGaA since October 1, 2009. She is full-time Member of the Works Council of the Darmstadt site of the Company.
Mechthild Auge	Dr. Mechthild Auge has been Member of the Supervisory Board and Employee Representative of Merck KGaA since March 25, 2009. He is Head of Strategy, CardioMetabolic Care, Merck Serono.
Johannes Baillou	Mr. Johannes Baillou is Member of the Supervisory Board of Merck KGaA. He is Entrepreneur and Vice Chairman of the Board of Partners of E. Merck KG. He is Managing Partner of Bondi Immobilien-Consulting GmbH. He serves as Member of the Finance Committee at the Company.
Frank Binder	Mr. Frank Binder is Member of the Supervisory Board of Merck KGaA. He is Entrepreneur. He has been Member of the Board of Partners of E. Merck KG since June 27, 2009. He is Chairman of the Board of Directors of BMR-Yachting AG and Landbell AG fuer Rueckhol-Systeme. Moreover, he is Chief Executive Officer of Novarca Deutschland GmbH. He was Member of the Board of Directors of Athena AG until December 16, 2011.
Wolfgang Buechele	Dr. Wolfgang Buechele has been Member of the Supervisory Board of Merck KGaA since July 1, 2009. He is Chief Executive Officer of BorsodChem Zrt. He has been Member of the Board of Partners of E. Merck KG since July 1, 2009. He is Member of the Board of Kemira Oij. He is Member of the Finance Committee at the Company.
Michael Fletterich	Mr. Michael Fletterich has been Member of the Supervisory Board and Employee Representative of Merck KGaA since July 1, 1998. He is Chairman of the Works Council of the Gernsheim site of the Company.
Michaela Freifrau von Glenck	Ms. Michaela Freifrau von Glenck is Member of the Supervisory Board of Merck KGaA. She is Teacher by profession.
Edeltraud Glaenzer	Mr. Edeltraud Glaenzer is Member of the Supervisory Board and Employee Representative of Merck KGaA. He is Member of the Managing Board of Industriegewerkschaft Bergbau, Chemie, Energie (IG BCE). He has served as Member of the Supervisory Board of Abbott Management GmbH/Abbott Holding GmbH until January 31, 2009. He is Member of the Board of B. Braun Melsungen AG and Vice Chairman of the Board of Solvay Deutschland GmbH.
Juergen Glaser
Hans-Juergen Leuchs	Dr. Hans-Juergen Leuchs has been Member of the Supervisory Board of Merck KGaA since July 1, 2009. He is retired graduate chemist. He has been Member of the Supervisory Board of Zeton BV since October 15, 2009. He has been Member of the Board of Partners E. Merck KG since July 1, 2009. He has been on the Supervisory Board of Zeton International Inc. since November 3, 2010. He is Member of the Research and Development Committee at the Company.
Albrecht Merck	Mr. Albrecht Merck has been Member of the Supervisory Board of Merck KGaA since January 1, 2005. He is Businessman by profession. He is Member of the Board of Partners of E. Merck KG. He is Commercial Director of the Castel Peter winery, Bad Duerkheim.
Karl-Heinz Scheider	Dr. Karl-Heinz Scheider has been Member of the Supervisory Board and Employee Representative of Merck KGaA since March 25, 2009. He is Chemist by profession. He is Head of Contract Manufacturing Chemicals at Merck KGaA.
Theo Siegert	Prof. Dr. Theo Siegert has been Member of the Supervisory Board at Merck KGaA since July 1, 2006. He had a career spanning more than 30 years with Franz Haniel & Cie. GmbH, where until the end of 2005, he held various executive management positions, most recently as Chairman of the Managing Board. He served as Member of the Supervisory Board of ERGO AG until May 12, 2010. He is Managing Partner of de Haen Carstanjen & Soehne. He is Member of the Supervisory Board of Deutsche Bank AG and E.ON AG. He has been Member of the Supervisory Board of Henkel AG & Co KGaA since April 2009. He is Member of the Board of Partners of E. Merck KG and Member of the Board of Directors of DKSH Holding Ltd. He is Chairman of the Finance Committee and Member of the Personnel Committee at the Company.
Berthold Wagner

Basic Compensation

Name	Fiscal Year Total
Rolf Krebs	79,318
Karl-Ludwig Kley	5,549,000
Heiner Wilhelm	59,488
Matthias Zachert	4,153,000
Kai Beckmann	3,653,000
Constantin Fest	--
Stefan Oschmann	4,400,000
Bernd Reckmann	4,405,000
Crocifissa Attardo	39,659
Mechthild Auge	39,659
Johannes Baillou	39,659
Frank Binder	39,659
Wolfgang Buechele	39,659
Michael Fletterich	39,659
Michaela Freifrau von Glenck	39,659
Edeltraud Glaenzer	39,659
Juergen Glaser	26,548
Hans-Juergen Leuchs	39,659
Albrecht Merck	39,659
Karl-Heinz Scheider	39,659
Theo Siegert	39,659
Berthold Wagner	25,464

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Rolf Krebs	0	0
Karl-Ludwig Kley	0	0
Heiner Wilhelm	0	0
Matthias Zachert	0	0
Kai Beckmann	0	0
Constantin Fest	0	0
Stefan Oschmann	0	0
Bernd Reckmann	0	0
Crocifissa Attardo	0	0
Mechthild Auge	0	0
Johannes Baillou	0	0
Frank Binder	0	0
Wolfgang Buechele	0	0
Michael Fletterich	0	0
Michaela Freifrau von Glenck	0	0
Edeltraud Glaenzer	0	0
Juergen Glaser	0	0
Hans-Juergen Leuchs	0	0
Albrecht Merck	0	0
Karl-Heinz Scheider	0	0
Theo Siegert	0	0
Berthold Wagner	0	0

Insider Trading

» Full list on Insider Trading

People: Merck KGaA (MKGAY.PK)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: